News & Updates

Adding androgen receptor signaling inhibitors (ARSI) to a treatment regimen consisting of docetaxel and androgen deprivation therapy (ADT) can lead to better survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC), according to a recent meta-analysis.

UGN-102, a nonsurgical, chemoablative gel used as a primary treatment for nonmuscle-invasive bladder cancer (NMIBC), is more patient-centred than standard treatments, according to a recent study.

Taking multivitamins regularly or for a long duration neither heightens nor reduces the risk of overall or aggressive prostate cancer among older, generally well-nourished men, results of a study have shown.

Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.

Urgency urinary incontinence is common among women with bacterial vaginosis, according to a study.